Please assess the completion status of the following clinical trial:

Trial Title: A Study of Naltrexone SR/ Bupropion SR in Overweight or Obese Subjects With Major Depression

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female and male subjects must be 18 to 65 years of age;~* Have body mass index (BMI) greater or equal to 27 and less than or to equal 43kg/m2;~* Meet criteria for major depression~* Women of child-bearing potential, must be non-lactating and agree to use effective contraception throughout the study period and 30 days after discontinuation of study drug;~* Able to comply with all required study procedures and schedule;~* Able to speak and read English;~* Willing and able to give written informed consent~Exclusion Criteria:~* Obesity of known endocrine origin~* Serious medical condition~* History of drug or alcohol abuse or dependence~* Use of excluded concomitant medications~* History of surgical or device (e.g. gastric banding) intervention for obesity;~* History or predisposition to seizures~* Pregnant or breast-feeding women or planning to become pregnant during the study period or within 30 days of discontinuing study drug;~* Planned surgical procedure that can impact the conduct of the study;~* Use of investigational drug, device or procedure within 30 days prior to Screening;~* Participation in any previous clinical trial conducted by Orexigen Therapeutics;~* Any condition which in the opinion of the investigator makes the subject unsuitable for inclusion in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- NB32 (Type: EXPERIMENTAL): Naltrexone SR 32 mg/Bupropion SR 360 mg/ day

Based on this trial design, predict the completion outcome and termination type (if applicable).